Un nuevo estudio sugiere que la serotonina podría empeorar los síntomas del tinnitus

Una nueva investigación muestra que la serotonina, un neurotransmisor potenciado por muchos antidepresivos, puede intensificar el tinnitus. Los científicos identificaron un circuito cerebral específico en ratones que vincula niveles más altos de serotonina con comportamientos que imitan esta afección auditiva.

Un equipo de la Oregon Health & Science University y la Anhui University en China publicó los hallazgos en la revista Proceedings of the National Academy of Sciences. Utilizaron optogenética para estimular las neuronas productoras de serotonina y observaron una mayor actividad en las regiones cerebrales auditivas, junto con respuestas similares al tinnitus en los ratones mediante una prueba de sobresalto modificada. El estudio se basa en trabajos anteriores de 2017 y coincide con los informes de algunos pacientes cuyo tinnitus empeora al tomar ISRS.

Artículos relacionados

Lab participants show stress and irritability from inaudible infrasound in a scientific study, with visualized low-frequency waves and cortisol monitors.
Imagen generada por IA

Study finds infrasound can raise cortisol and irritability even when people can’t hear it

Reportado por IA Imagen generada por IA Verificado por hechos

A small controlled experiment reported in Frontiers in Behavioral Neuroscience found that exposure to infrasound—ultra-low-frequency vibration below the range of human hearing—was associated with higher salivary cortisol and more negative mood ratings, even though participants could not reliably detect when the infrasound was present.

Researchers have shown that stimulating specific brain activity in awake mice produces some of the restorative effects of deep sleep, including improved memory. The team now plans to explore whether a similar approach could work in people.

Reportado por IA

A widely studied anti-aging treatment triggered significant brain damage in mice, according to new research from the University of Connecticut. The drug combination dasatinib plus quercetin caused myelin loss and changes resembling those seen in multiple sclerosis. The findings raise questions about its use in longevity studies and off-label therapies.

A proof-of-concept randomized clinical trial published online May 20, 2026, in JAMA Psychiatry found signals that tocilizumab—an anti-inflammatory drug used for immune-mediated conditions including rheumatoid arthritis—may improve some symptoms in adults with moderate-to-severe depression who had a poor response to antidepressants and evidence of low-grade inflammation.

Reportado por IA

New research indicates that oestrogen levels, which vary across the menstrual cycle, can influence how efficiently some drugs reach the brain in women.

Este sitio web utiliza cookies

Utilizamos cookies para análisis con el fin de mejorar nuestro sitio. Lee nuestra política de privacidad para más información.
Rechazar